Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase

[1]  F. Mahmoud,et al.  The role of C-reactive protein as a prognostic indicator in advanced cancer , 2002, Current oncology reports.

[2]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Benner,et al.  Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100β or melanoma inhibitory activity (MIA)? , 2001, Melanoma research.

[4]  Waldmann,et al.  Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. , 2000, Journal of experimental & clinical cancer research : CR.

[5]  A. Benner,et al.  S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Nozoe,et al.  Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. , 1998, American journal of surgery.

[7]  R. Dummer,et al.  Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Probst-Kepper,et al.  Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. , 1998, British Journal of Cancer.

[9]  Q. Dong,et al.  Prognostic factors for survival of patients treated systemically for disseminated melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Fearon,et al.  Metabolic disturbance and sensitivity to endotoxin in patients with advanced cancer: relationship to lymphocyte reactivity, tumour necrosis factor (TNF) production and survival , 1996, Clinical and experimental immunology.

[11]  M. Weil,et al.  Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  A. Buzaid,et al.  lnterleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1 , 1996, Melanoma research.

[13]  J. Blay,et al.  Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Kopf,et al.  The incidence of malignant melanoma in the United States: issues as we approach the 21st century. , 1996, Journal of the American Academy of Dermatology.

[15]  E. Tartour,et al.  Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. , 1994, British Journal of Cancer.

[16]  M. Herlyn,et al.  Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes , 1994, International journal of cancer.

[17]  D. Bajorin,et al.  Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis , 1993, Cancer.

[18]  R. Kerbel,et al.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr;121(2):following 477] , 1993, The Journal of cell biology.

[19]  M. Colombo,et al.  Expression of cytokine genes, including IL‐6, in human malignant melanoma cell lines , 1992, Melanoma research.

[20]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.

[21]  D. Morton,et al.  Interleukin-6 production by human melanoma cell lines. , 1992, Lymphokine and cytokine research.

[22]  T. Hirano.  Interleukin-6 and its relation to inflammation and disease. , 1992, Clinical immunology and immunopathology.

[23]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[24]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[25]  P. Heinrich,et al.  Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes , 1989, FEBS letters.

[26]  B. Hazenberg,et al.  The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. , 1988, Biochemical and biophysical research communications.

[27]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.